Hikma Pharmaceuticals PLC (HIK.L) reported Thursday that its first-half core profit attributable to shareholders was $284 million, up 36 percent compared to $209 million a year ago. Core basic earnings per share were 128.5 cents, up from 92.1 cents in the prior year.
Group revenue went up 18 percent to $1.43 billion from $1.21 billion last year, with strong growth in all three business segments. Revenue grew 19 percent at constant currency rates.
Further, the Board is recommending an interim dividend of 25 cents per share, up 32 percent from last year, to be paid on September 15 to eligible shareholders on the register at the close of business on August 11.
Looking ahead, the company continues to expect Injectables revenue growth of between 7 percent and 9 percent and for core operating margin to be between 36 percent and 37 percent.
The company still expects Branded revenue growth to be in the mid to high-single digits in constant currency.
For Generics, the company now projects revenue growth of close to 30 percent, up from previous guidance of revenue growth close to 20 percent, and for core operating margin to be between 18 percent and 20 percent, up from 16 percent to 18 percent expected earlier.
In London, Hikma shares were trading at 2,127 pence, up 2.51 percent.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.